Clinical trials: Overweight, Obesity
Hypertension, Overweight or Obesity
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1
GZL1 is an independent study conducted under the GZPL master protocol. GZL1 will evaluate the efficacy and safety of orforglipron for treatment of hypertension in participants with obesity or overweight.
- Trial name
- NCT06948435
- Testing
- Orforglipron
- Where
- 99 sites in United States, Argentina and 9 more
- Volunteers
- 487 people
- Sponsor
- Eli Lilly and Company
Obesity
Noom Coach for Bariatric Health
Mobile technologies/smartphone applications offer a means to effect behavior change without significant obstacles that typically limit implementation of empirically supported therapies (e.g., in-person sessions); however…
- Trial name
- NCT03887078
- Testing
- Noom Coach for Bariatric Health
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Noom Inc.
Obesity, Overweight
A Study to Investigate the Effect of LY4086940 Versus Placebo in Participants With Obesity or Overweight and Without Type 2 Diabetes
The purpose of this study, performed under the master protocol W8M-MC- CWMM (NCT06143956), is to evaluate the efficacy and safety of LY4086940 compared with placebo in participants without type 2 diabetes who have obesity or who…
- Trial name
- NCT07890376
- Testing
- LY4086940
- Where
- 46 sites in United States, Argentina
- Volunteers
- 460 people
- Sponsor
- Eli Lilly and Company
Overweight/Obesity
The Evaluation of Bioequivalence Between a Single-dose Pen and a Multi-dose Pen of HRS9531 Injection Solution
The study is being conducted to evaluate the bioequivalence between a single-dose pen and a multi-dose pen of HRS9531 injection solution.
- Trial name
- NCT06792955
- Testing
- HRS9531 injection
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.
Ulcerative Colitis, Crohn Disease
Systems Biology of Gastrointestinal and Related Diseases
This is a longitudinal observational study on patients with gastrointestinal and related disease. The study will be conducted for at least 10 years, following each participant over time, as they either go through relapses and…
- Conditions
- Ulcerative Colitis, Crohn Disease, Obesity, Colon Polyp
- Trial name
- NCT05579444
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Viome
Prader-Willi Syndrome
Study to Assess the Efficacy and Safety of Eutropin in Prader-Willi Syndrome
Evaluate the efficacy and safety after treatment of Eutropin® inj. compared to Genotropin® in infants/toddlers with Prader-Willi syndrome
- Trial name
- NCT02204163
- Testing
- Eutropin, Genotropin
- Where
- 3 sites in South Korea
- Volunteers
- 34 people
- Sponsor
- LG Life Sciences
Obesity
A Research Study to See How Well Different Doses of CagriSema Help People With Excess Body Weight Lose Weight
This study will look at how well CagriSema helps people with excess body weight lose weight. CagriSema is a new medicine developed by Novo Nordisk that combines cagrilintide and semaglutide.
- Trial name
- NCT06388187
- Testing
- Cagrilintide, Semaglutide
- Where
- 25 sites in United States, Canada and 3 more
- Volunteers
- 300 people
- Sponsor
- Novo Nordisk A/S
Obesity & Overweight
Safety and Tolerability of a Nutritional Formula Designed to Aid in Maintenance of Muscle During Periods of Caloric Restriction in Adults
Muscle loss during caloric restriction is a significant concern for metabolic health and physical function, yet there is limited evidence on interventions that simultaneously target multiple contributing pathways.
- Trial name
- Redefine (NCT07447843)
- Testing
- Redefine
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Nature's Sunshine Products, Inc.
Otherwise Healthy Overweight or Obese
A Study of Safety, Tolerability, and Pharmacokinetics of Multiple-Ascending Doses of PHP-303 in Otherwise Healthy Overweight or Obese Subjects
This is a Phase 1, randomized, double-blind, placebo-controlled multiple-ascending dose (MAD) study designed to evaluate the safety, tolerability, and pharmacokinetics (PK) of PHP-303 in otherwise healthy overweight or obese…
- Trial name
- NCT03775278
- Testing
- PHP-303
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- pH Pharma
Obstructive Sleep Apnea, Obesity Hypoventilation Syndrome (OHS)
Evaluation of Auto-EPAP for Management of Upper Airway Obstruction During Non-Invasive Ventilation
To evaluate the safety and effectiveness of the Automatic Expiratory Positive Airway Pressure (Auto-EPAP) feature versus manual expiratory positive airway pressure (EPAP) in the Vivo 45 LS Ventilator.
- Conditions
- Obstructive Sleep Apnea, Obesity Hypoventilation Syndrome (OHS), Chronic Obstructive Pulmonary Disease (COPD), Neuromuscular Diseases (NMD)
- Trial name
- Vivo NOVA (NCT06560411)
- Testing
- Non-Invasive Ventilation
- Where
- 4 sites in United States
- Volunteers
- 23 people
- Sponsor
- Breas Medical, Inc.
Healthy Subjects;Overweight or Obesity
A Phase 1 Study of GZC8072 Tablets Following a Single Dose in Healthy Study Participants and Multiple Doses in Obese/Overweight Study Participants
This trial is conducted in China. This study plans to include 2 parts, i.e., a single-dose study and a multiple-dose study: The single-dose study will be conducted in healthy adult participants to evaluate the safety…
- Trial name
- NCT07784699
- Testing
- GZC8072 Tablets
- Where
- China
- Volunteers
- 126 people, healthy volunteers welcome
- Sponsor
- Gan & Lee Pharmaceuticals.
Obesity, Weight Loss
Attitudes Toward Food During a Weight Loss Intervention
The purpose of this study is to evaluate whether the Noom Healthy Weight Program, a digital behavior change weight loss intervention, creates a positive relationship with food, compared to a waitlist control group.
- Conditions
- Obesity, Weight Loss, Overweight and Obesity, Overweight or Obesity
- Trial name
- NCT04586647
- Testing
- Noom Healthy Weight; mobile behavior change program for weight loss.
- Where
- United States
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- Noom Inc.
Metabolism and Nutrition Disorder, Obesity
A Trial to Assess the Effects of Liraglutide on Gallbladder Emptying in Overweight and Obese Subjects.
This trial is conducted in Europe. The aim of this trial is to investigate the effects of liraglutide on gallbladder emptying in overweight and obese subjects.
- Trial name
- NCT02717858
- Testing
- liraglutide
- Where
- Denmark
- Volunteers
- 52 people
- Sponsor
- Novo Nordisk A/S
Nicotine Dependence, Overweight
A Study of Naltrexone SR/ Bupropion SR in Overweight and Obese Subjects Who Are Nicotine-Dependent
The purpose of this study is to determine whether a combination of naltrexone SR and bupropion SR is safe and effective in the treatment of nicotine-dependence in overweight and obese subjects.
- Conditions
- Nicotine Dependence, Overweight, Obesity
- Trial name
- NCT00563563
- Testing
- NB32, Ancillary therapy
- Where
- 3 sites in United States
- Volunteers
- 30 people
- Sponsor
- Orexigen Therapeutics, Inc
Obesity
A Study to Assess Safety, Tolerability, and Pharmacokinetics of MEDI0382 in Non-diabetic Obese Participants
This is a Phase 1, randomized, blinded, placebo-controlled study in up to approximately 51 non-diabetic obese participants with a body mass index (BMI) ≥ 35 kg/m^2.
- Trial name
- NCT03625778
- Testing
- MEDI0382
- Where
- 2 sites in United States
- Volunteers
- 51 people
- Sponsor
- MedImmune LLC
Obesity
Reinforcement of Surgical Staple Lines Using Peri-Strips Dry (PSD) With Veritas Collagen Matrix
The purpose of this study is to verify the performance of PSD Veritas to provide staple line protection during surgical procedures for obesity.
- Trial name
- RESULTS (NCT00566943)
- Testing
- PSD Veritas Collagen Matrix, Roux-en-Y gastric by-pass surgery with no buttress
- Where
- United States
- Volunteers
- 101 people
- Sponsor
- Baxter Healthcare Corporation
Nonalcoholic Steatohepatitis (NASH)
A Clinical Study to Evaluate the Efficacy and Safety of Aramchol in Subjects With NASH (ARMOR)
An Open-Label Part was added: This part will enroll in selected sites which are less affected by the COVID-19 pandemic. 150 subjects with NASH and fibrosis confirmed by liver histology (F1-F3) will be randomized into 3 groups…
- Trial name
- ARMOR (NCT04104321)
- Testing
- Aramchol free acid
- Where
- 2 sites in United States
- Volunteers
- 157 people
- Sponsor
- Galmed Research and Development, Ltd.
Obesity & Overweight
UBT251 Injection Phase Ⅲ Study (Overweight or Obesity)
This randomized, double-blind, parallel, placebo-controlled phase Ⅲ study to evaluate the efficacy and safety of UBT251 Injection in overweight/obese patients
- Trial name
- NCT07648225
- Testing
- UBT251 Injection 4.0 mg, UBT251 Injection 6.0 mg
- Where
- China
- Volunteers
- 600 people
- Sponsor
- The United Bio-Technology (Hengqin) Co., Ltd.
Obesity
A Tolerance and Pharmacokinetic Study of Trodusquemine in Healthy Volunteers
The purpose of this study is to evaluate the safety and tolerance of single intravenous (through a vein) doses of trodusquemine. Different amounts of trodusquemine will be given to each volunteer group throughout the study.
- Trial name
- NCT00509132
- Testing
- trodusquemine
- Where
- United States
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Genaera Corporation
Obesity
Clinical Trial of Safety and Efficacy of Various Dosage Schedules for Dietressa Drug in Treatment of Obese Patients
The purpose of this study is: To assess safety of Dietressa in the dose of 6 tablets daily within 24 weeks in treatment of obese patients.
- Trial name
- NCT01535014
- Testing
- Dietressa
- Where
- 17 sites in Russia
- Volunteers
- 493 people
- Sponsor
- Materia Medica Holding
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.